PL1749090T3 - Sposób formułowania i kompozycja do terapii komórkowej - Google Patents

Sposób formułowania i kompozycja do terapii komórkowej

Info

Publication number
PL1749090T3
PL1749090T3 PL05724065T PL05724065T PL1749090T3 PL 1749090 T3 PL1749090 T3 PL 1749090T3 PL 05724065 T PL05724065 T PL 05724065T PL 05724065 T PL05724065 T PL 05724065T PL 1749090 T3 PL1749090 T3 PL 1749090T3
Authority
PL
Poland
Prior art keywords
composition
cell therapy
formulation method
therapy formulation
cell
Prior art date
Application number
PL05724065T
Other languages
English (en)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies, Ltd. filed Critical Immunovative Therapies, Ltd.
Publication of PL1749090T3 publication Critical patent/PL1749090T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/51B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50Cell markers; Cell surface determinants
    • C12N2501/515CD3, T-cell receptor complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00Microcarriers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00Supports or coatings for cell culture, characterised by material
    • C12N2533/30Synthetic polymers
    • C12N2533/40Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PL05724065T 2004-03-01 2005-03-01 Sposób formułowania i kompozycja do terapii komórkowej PL1749090T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54903204P 2004-03-01 2004-03-01
PCT/US2005/006446 WO2005084276A2 (en) 2004-03-01 2005-03-01 Cell therapy formulation method and composition
EP05724065.7A EP1749090B1 (en) 2004-03-01 2005-03-01 Cell therapy formulation method and composition

Publications (1)

Publication Number Publication Date
PL1749090T3 true PL1749090T3 (pl) 2017-12-29

Family

ID=34919427

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05724065T PL1749090T3 (pl) 2004-03-01 2005-03-01 Sposób formułowania i kompozycja do terapii komórkowej

Country Status (10)

Country Link
EP (2) EP1749090B1 (pl)
JP (3) JP5144250B2 (pl)
CA (1) CA2530514C (pl)
DK (1) DK1749090T3 (pl)
ES (1) ES2635868T3 (pl)
HU (1) HUE035726T2 (pl)
IL (3) IL173405A (pl)
PL (1) PL1749090T3 (pl)
PT (1) PT1749090T (pl)
WO (1) WO2005084276A2 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US7592431B2 (en) * 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
PL2573166T3 (pl) 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej
PH12013502252B1 (en) 2011-05-03 2018-09-21 Immunovative Therapies Ltd Induction of il-12 using immunotherapy
PL2704741T3 (pl) 2011-05-03 2018-02-28 Immunovative Therapies, Ltd. Sposoby postępowania z lekami biologicznymi zawierającymi żywe komórki
CN105899219B (zh) 2014-01-08 2021-08-13 免疫创新治疗有限公司 人类免疫缺陷病毒/获得性免疫缺陷综合症的治疗

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
AU7873187A (en) 1986-08-08 1988-02-24 University Of Minnesota Method of culturing leukocytes
US6905680B2 (en) * 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) * 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
US5728388A (en) 1989-10-03 1998-03-17 Terman; David S. Method of cancer treatment
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
WO1994012196A1 (en) * 1992-11-25 1994-06-09 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
AU7052194A (en) * 1993-06-04 1995-01-03 Regents Of The University Of Michigan, The Methods for selectively stimulating proliferation of t cells
DE69430315T2 (de) 1993-08-06 2002-11-21 Epimmune, Inc. Methoden zur (ex vivo) therapie mittels peptid - bestueckten antigen - praesentierenden zellen zur aktivierung von ctl
AU1333195A (en) * 1994-06-03 1996-01-04 Dana-Farber Cancer Institute Methods for selectively stimulating proliferation of t cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DK0814838T3 (da) 1995-03-08 2003-09-15 Scripps Research Inst Antigenpræsenterende system og aktivering af T-celler
EP0966523A1 (en) 1997-01-31 1999-12-29 Hemosol Inc. Method for the production of selected lymphocytes
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US20040258661A1 (en) * 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
AU2003202908A1 (en) * 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
PL2573166T3 (pl) * 2004-02-26 2016-11-30 Sposoby otrzymywania komórek T do terapii komórkowej

Also Published As

Publication number Publication date
JP5649551B2 (ja) 2015-01-07
WO2005084276A2 (en) 2005-09-15
IL173405A0 (en) 2006-06-11
IL173405A (en) 2011-02-28
ES2635868T3 (es) 2017-10-05
PT1749090T (pt) 2017-08-28
CA2530514A1 (en) 2005-09-15
IL210244A0 (en) 2011-03-31
DK1749090T3 (en) 2017-09-04
IL223938B (en) 2020-01-30
JP5144250B2 (ja) 2013-02-13
CA2530514C (en) 2017-01-31
JP2014077018A (ja) 2014-05-01
JP2012021033A (ja) 2012-02-02
JP2007526314A (ja) 2007-09-13
EP1749090A4 (en) 2009-04-29
EP1749090A2 (en) 2007-02-07
HUE035726T2 (en) 2018-05-28
EP1749090B1 (en) 2017-05-17
WO2005084276A3 (en) 2007-05-10
EP3202895A1 (en) 2017-08-09

Similar Documents

Publication Publication Date Title
HRP20161210T1 (hr) Formulacija obložene tablete i postupak
GB0422525D0 (en) Dermatological compositions and methods
IL176831A0 (en) Direct compression formulation and process
IL189079A0 (en) Method of encapsulating therapeutic substances in cells
GB0505446D0 (en) Polishing composition and polishing method
SG115831A1 (en) Polishing composition and polishing method
IL177793A0 (en) Method and composition for burned skin
GB2412919B (en) Polishing composition and polishing method
EP1841397A4 (en) TRICHOLOGY FORMULATIONS AND TREATMENTS
GB0416252D0 (en) Cosmetic method and composition
GB0608398D0 (en) Pharmaceutical composition and method of using same
IL184062A0 (en) Visco-supplement composition and methods
SG115786A1 (en) Polishing composition and polishing method
PL1749090T3 (pl) Sposób formułowania i kompozycja do terapii komórkowej
GB0403008D0 (en) Composition and method
ZA200706038B (en) Visco-supplement composition and methods
GB0403696D0 (en) Process and composition
EP1812032A4 (en) TISSUE FACTOR COMPOSITION AND RELATED METHODS
GB0608399D0 (en) Pharmaceutical composition and method of using same
GB0407993D0 (en) Therapeutic methods and compositions for use therein
GB0418363D0 (en) Therapeutic methods and compositions for use therein
GB0426756D0 (en) Composition and method
GB0425737D0 (en) Composition and method
GB0417415D0 (en) Composition and method
GB0411093D0 (en) Method and composition